BridgeBio Pharma Inc Stock Research

Market Summary

USD13.54-0.21

Market Closed

-1.53%

BBIO Alerts

2 major insider sales recently.

BBIO Stock Price

BBIO RSI Chart

BBIO Valuation

Market Cap

2.2B

Price/Earnings (Trailing)

-4.48

Price/Sales (Trailing)

20.12

Price/Free Cashflow

-5.34

BBIO Price/Sales (Trailing)

BBIO Profitability

Return on Equity

38.98%

Return on Assets

-77.79%

Free Cashflow Yield

-18.74%

BBIO Fundamentals

BBIO Revenue

Revenue (TTM)

107.9M

Revenue Y/Y

-100%

Revenue Q/Q

-100%

BBIO Earnings

Earnings (TTM)

-484.7M

Earnings Y/Y

7.69%

Earnings Q/Q

-0.27%

Price Action

52 Week Range

5.7419.95

(Low)(High)

Last 7 days

-0.9%

Last 30 days

-6.7%

Last 90 days

19.9%

Trailing 12 Months

87.0%

BBIO Financial Health

Current Ratio

4.52

BBIO Investor Care

Shares Dilution (1Y)

8.63%

Diluted EPS (TTM)

-2.84

Peers (Alternatives to BridgeBio Pharma)

View All Peers In Detail

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
AMGN	116.8B	26.2B	-8.85%	-12.37%	14.75	4.46	-0.48%	38.34%
GILD	95.3B	27.0B	-7.15%	22.78%	17.06	3.52	-1.56%	23.65%
MRNA	49.5B	15.1B	-3.01%	-12.71%	10.35	3.29	-33.37%	-67.32%
BIIB	43.1B	10.1B	-1.82%	44.85%	13.78	4.27	-6.61%	115.98%
MID-CAP
NBIX	8.8B	1.6B	-10.82%	-3.21%	137.28	5.5	32.38%	-10.36%
DNLI	4.0B	-	17.83%	16.01%	-10.8	36.9	122.90%	-29.67%
BEAM	2.4B	76.7M	3.87%	-11.56%	-7.51	30.96	41.73%	-32.75%
BBIO	2.2B	107.9M	-6.75%	87.02%	-4.48	20.12	54.84%	17.36%
SMALL-CAP
RCUS	1.5B	119.0M	13.50%	5.58%	-5.31	12.45	-69.61%	-584.39%
REPL	1.1B	10.0M	10.82%	23.60%	-6.03	105.01	215.65%	-47.65%
NVAX	641.1M	-	-3.13%	-86.56%	-0.55	0.32	72.89%	12.32%
FATE	487.0M	136.9M	-18.29%	-78.97%	-2.07	3.56	116.83%	-0.93%
SGMO	191.0M	241.0M	-22.11%	-68.89%	-1.5	0.79	113.96%	27.87%
VXRT	166.8M	697.0K	51.20%	-67.02%	-1.55	239.29	47.98%	-35.48%
IBIO	9.0M	-	-32.41%	-88.55%	-0.12	3.21	0.51%	-129.47%

Financials for BridgeBio Pharma

* denotes actual numbers (not divided by Millions)
Income Statement (Last 12 Months)					(In Millions)
Description	(%) Q/Q	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4
Revenue	9.7%	108	98.00	89.00	79.00	70.00
S&GA Expenses	-13.8%	143	166	181	191	-
R&D Expenses	-7.3%	399	431	443	436	-
EBITDA	-	556	-	-	-	-
EBITDA Margin	-	7.97*	-	-	-	-
EBT Margin	-	7.25*	-	-	-	-
Interest Expenses	6.4%	80.00	76.00	67.00	57.00	-
Net Income	2.4%	-484	-496	-517	-616	-586
Net Income Margin	11.0%	-4.49*	-5.04*	-7.42*	-	-
Free Cahsflow	9.1%	-424	-466	-458	-519	-

Balance Sheet					(In Millions)
Description	(%) Q/Q	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1
Assets	0.4%	626	623	729	862	813
Current Assets	0.7%	553	549	642	771	716
Cash Equivalents	8.1%	407	377	483	470	372
Net PPE	-6.9%	14.00	15.00	16.00	17.00	17.00
Liabilities	-1.5%	1,839	1,868	1,859	1,877	1,854
Current Liabilities	-20.4%	97.00	121	119	141	103
LT Debt, Non Current	1.1%	436	431	434	-	-
Shareholder's Equity	2.4%	-1,213	-1,243	-1,041	-	-
Retained Earnings	-7.3%	-2,057	-1,918	-1,780	-1,643	-1,633
Additional Paid-In Capital	17.9%	1,107	939	917	893	868
Shares Outstanding	6.5%	160	151	149	148	148
Minority Interest	8.6%	12.00	11.00	10.00	12.00	-0.03

* denotes actual numbers (not divided by Millions)
Cashflow (Last 12 Months)					(In Millions)
Description	(%) Q/Q	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1
Cashflow From Operations	3.9%	-403	-419	-460	-446	-507
Share Based Compensation	-2.4%	89.00	92.00	90.00	88.00	90.00
Cashflow From Investing	-27.9%	327	453	457	369	220
Cashflow From Financing	1145.2%	137	-13.13	306	169	188
Buy Backs	-	0.00	-	-	-	-

Risks for BBIO

What is the probability of a big loss on BBIO?

93.7%

Probability that BridgeBio Pharma stock will be more than 20% underwater in next one year

88.9%

Probability that BridgeBio Pharma stock will be more than 30% underwater in next one year.

63.3%

Probability that BridgeBio Pharma stock will be more than 40% underwater in next one year.

*Calculated based on probability distribution of losses observed in actual data in the last 5 years.

How does BBIO drawdown profile look like?

Y-axis is the maximum loss one would have experienced if BridgeBio Pharma was unfortunately bought at previous high price.

Drawdowns

Returns for BBIO

Cumulative Returns on BBIO

-22.7%

3-Year Cumulative Returns

Which funds bought or sold BBIO recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
2023-05-26	ProShare Advisors LLC	reduced	-11.66	182,597	380,610	-%
2023-05-23	Capital Impact Advisors, LLC	reduced	-15.31	209,764	458,702	0.56%
2023-05-22	PUTNAM INVESTMENTS LLC	added	38.41	532,843	797,730	-%
2023-05-22	AMERIPRISE FINANCIAL INC	reduced	-38.04	160,740	623,740	-%
2023-05-18	JPMORGAN CHASE & CO	reduced	-36.43	1,546,000	5,577,000	-%
2023-05-18	NEW YORK STATE COMMON RETIREMENT FUND	reduced	-23.07	371,000	922,000	-%
2023-05-16	PERCEPTIVE ADVISORS LLC	added	12.37	18,687,200	31,618,600	0.93%
2023-05-16	SUSQUEHANNA INTERNATIONAL GROUP, LLP	added	576	8,118,160	8,709,610	-%
2023-05-16	JANE STREET GROUP, LLC	added	196	2,241,080	2,653,000	-%
2023-05-16	Rockefeller Capital Management L.P.	added	8.57	470,000	815,000	-%

Latest Funds Activity

Are funds buying BBIO calls or puts?

Calls

Puts

Are funds bullish or bearish(Calls - Puts)?

Net Call Options

No. of funds that own BBIO

No. of Funds

BBIO Alerts

2 major insider sales recently.

BridgeBio Pharma News

Schedule 13G FIlings of BridgeBio Pharma

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 14, 2023	kumar neil	6.42%	9,823,908	SC 13G/A
Feb 09, 2023	vanguard group inc	7.09%	10,591,455	SC 13G/A
Feb 08, 2023	state street corp	5.92%	8,844,943	SC 13G
Feb 01, 2023	blackrock inc.	6.6%	9,834,401	SC 13G/A
Feb 15, 2022	perceptive advisors llc	4.8%	7,128,755	SC 13G/A
Feb 14, 2022	kumar neil	6.05%	9,003,211	SC 13G/A
Feb 09, 2022	vanguard group inc	6.34%	9,331,683	SC 13G/A
Feb 03, 2022	blackrock inc.	6.3%	9,275,590	SC 13G/A
Feb 17, 2021	kkr genetic disorder l.p.	20.9%	31,060,971	SC 13D/A
Feb 16, 2021	american international group, inc.	2.8%	3,381,412	SC 13G/A

BBIO Fair Value

Show Fair-Value

Recent SEC filings of BridgeBio Pharma

View All Filings

Date Filed	Form Type	Document
May 18, 2023	4	Insider Trading
May 18, 2023	4	Insider Trading
May 18, 2023	4	Insider Trading
May 17, 2023	144	Notice of Insider Sale Intent
May 17, 2023	144	Notice of Insider Sale Intent
May 05, 2023	4	Insider Trading
May 05, 2023	4	Insider Trading
May 04, 2023	10-Q	Quarterly Report
May 04, 2023	S-8	Employee Benefits Plan
May 04, 2023	S-3ASR	S-3ASR

Latest Insider Trading transactions for BBIO

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
2023-05-17	Kumar Neil	sold	-722,218	14.0095	-51,552	ceo and president
2023-05-17	STEPHENSON BRIAN C	sold	-342,168	14.0095	-24,424	secretary, treasurer & cfo
2023-05-16	HOMCY CHARLES J	acquired	-	-	3,759	-
2023-05-16	Kumar Neil	acquired	-	-	102,249	ceo and president
2023-05-16	STEPHENSON BRIAN C	sold (taxes)	-289,859	14.09	-20,572	secretary, treasurer & cfo
2023-05-16	Kumar Neil	sold (taxes)	-714,321	14.09	-50,697	ceo and president
2023-05-16	STEPHENSON BRIAN C	acquired	-	-	44,996	secretary, treasurer & cfo
2023-05-16	HOMCY CHARLES J	sold (taxes)	-18,317	14.09	-1,300	-
2023-05-03	STEPHENSON BRIAN C	sold	-920,693	14.18	-64,929	secretary, treasurer & cfo
2023-05-03	Kumar Neil	sold	-1,701,740	14.1812	-120,000	ceo and president

About BridgeBio Pharma

Neil Kumar

www.bridgebio.com

580

BridgeBio Pharma, Inc. engages in the discovery, development, and delivery of various medicines for genetic diseases. The company has a pipeline of 30 development programs that include product candidates ranging from early discovery to late-stage development. Its products in development programs include AG10 and BBP-265, a small molecule stabilizer of transthyretin, or TTR that is in Phase 3 clinical trial for the treatment of TTR amyloidosis-cardiomyopathy, or ATTR-CM; BBP-831, a small molecule selective FGFR1-3 inhibitor, which is Phase 2 clinical trial to treat achondroplasia in pediatric patients; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD. The company also develops Encaleret, a small molecule antagonist of the calcium sensing receptor, or CaSR, which is in phase 2 proof-of-concept clinical trial for Autosomal Dominant Hypocalcemia Type 1, or ADH1; and BBP-711 for the treatment of hyperoxaluria, as well as patients suffering from recurrent kidney stones. In addition, it engages in developing products for Mendelian, oncology, and gene therapy diseases. BridgeBio Pharma, Inc. has license and collaboration agreements with the Leland Stanford Junior University; and The Regents of the University of California; Leidos Biomedical Research, Inc. The company was founded in 2015 and is headquartered in Palo Alto, California.

BBIO Income Statement

2023-03-31

Condensed Consolidated Statements of Operations (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Revenue:
Total revenue	$ 1,826	$ 1,694
Operating costs and expenses:
Cost of license revenue and products sold	651	1,348
Research and development	92,861	107,649
Selling, general and administrative	31,108	43,713
Restructuring, impairment and related charges	3,369	22,662
Total operating costs and expenses	127,989	175,372
Loss from operations	(126,163)	(173,678)
Other income (expense), net:
Interest income	4,153	267
Interest expense	(20,121)	(20,344)
Other expense, net	(601)	(7,575)
Total other income (expense), net	(16,569)	(27,652)
Net loss	(142,732)	(201,330)
Net loss attributable to redeemable convertible noncontrolling interests and noncontrolling interests	2,576	4,933
Net loss attributable to common stockholders of BridgeBio	$ (140,156)	$ (196,397)
Net loss per share attributable to common stockholders of BridgeBio, basic	$ (0.92)	$ (1.35)
Net loss per share attributable to common stockholders of BridgeBio, diluted	$ (0.92)	$ (1.35)
Weighted-average shares used in computing net loss per share attributable to common stockholders of BridgeBio, basic	152,645,635	145,882,149
Weighted-average shares used in computing net loss per share attributable to common stockholders of BridgeBio, diluted	152,645,635	145,882,149
License and Services Revenue
Revenue:
Total revenue	$ 1,826	$ 235
Product Sales
Revenue:
Total revenue		$ 1,459

BBIO Balance Sheet

2023-03-31

Condensed Consolidated Balance Sheets - USD ($)
$ in Thousands

Mar. 31, 2023

Dec. 31, 2022

Current assets:

Cash and cash equivalents

$ 407,368

$ 376,689

^[1]

Marketable securities

34,122

51,580

^[1]

Investment in equity securities

49,803

43,653

^[1]

Receivable from licensing and collaboration agreements

10,761

17,079

^[1]

Restricted cash

25,503

37,930

^[1]

Prepaid expenses and other current assets

25,145

21,922

^[1]

Total current assets

552,702

548,853

^[1]

Property and equipment, net

13,566

14,569

^[1]

Operating lease right-of-use assets

10,532

10,678

^[1]

Intangible assets, net

28,113

28,712

^[1]

Other assets

20,767

20,224

^[1]

Total assets

625,680

623,036

^[1]

Current liabilities:

Accounts payable

4,076

11,558

^[1]

Accrued compensation and benefits

18,869

31,256

^[1]

Accrued research and development liabilities

37,064

39,803

^[1]

Accrued professional services

4,015

1,790

^[1]

Operating lease liabilities, current portion

3,674

3,675

^[1]

Deferred revenue, current portion

6,675

8,156

^[1]

Other accrued liabilities

22,223

25,190

^[1]

Total current liabilities

96,596

121,428

^[1]

Term loan, net

435,764

430,993

^[1]

Operating lease liabilities, net of current portion

11,904

12,274

^[1]

Other long-term liabilities

17,501

26,643

^[1]

Total liabilities

1,839,293

1,867,960

^[1]

Commitments and contingencies (Note 8)

Redeemable convertible noncontrolling interests

(204)

(1,589)

Stockholders’ equity (deficit):

Undesignated preferred stock, $0.001 par value; 25,000,000 shares authorized; no shares issued and outstanding

Common stock, $0.001 par value; 500,000,000 shares authorized;166,626,999 shares issued and 160,435,238 shares outstanding as of March 31, 2023, 156,817,333 shares issued and 150,625,572 shares outstanding as of December 31, 2022

167

157

^[1]

Treasury stock, at cost; 6,191,761 shares as of March 31, 2023 and December 31, 2022

(275,000)

^[1]

Additional paid-in capital

1,106,635

938,703

^[1]

Accumulated other comprehensive loss

(12)

(328)

^[1]

Accumulated deficit

(2,057,455)

(1,918,149)

^[1]

Total BridgeBio stockholders' deficit

(1,225,665)

(1,254,617)

^[1]

Noncontrolling interests

12,256

11,282

^[1]

Total stockholders' deficit

(1,213,409)

(1,243,335)

^[1],[2]

Total liabilities, redeemable convertible noncontrolling interests and stockholders' deficit

625,680

623,036

^[1]

2029 Notes

Current liabilities:

Notes, net

735,463

734,988

^[1]

2027 Notes

Current liabilities:

Notes, net

$ 542,065

$ 541,634

^[1]

[1]	The condensed consolidated balance sheet as of December 31, 2022 is derived from the audited consolidated financial statements as of that date.
[2]	The consolidated balances as of December 31, 2022 and 2021 are derived from the audited consolidated financial statements as of those dates.